Avoiding pitfalls in the management of epilepsy
A C F Hui許志輝, H M Yeung楊漢明
HK Pract 2001;23:246-250
Summary
Epilepsy is a common disorder. There is a substantial literature on its management.
This article summarises practical information for family physicians. It highlights
the common mistakes in the care of patients with recurrent seizures by emphasing
the importance of making a correct and specific diagnosis, the use of appropriate
anticonvulsants and treatment of refractory epilepsy.
摘要
癲癇是一種常見疾病,有關其治療的文獻甚多。 本文的目的在於對家庭醫生治療癲癇病人時可用的實 用信息加以總結。通過強調對患頑固性癲癇的病人的 正確和明確的診斷、抗痙攣藥物的選擇和應用、治療
方案的選擇和應用的重要性,我們突出了在癲癇反覆 發作的病人之治療中的常見錯誤。
Introduction
There have been great advances in understanding the aetiology, investigation and
management of epilepsies.1-3 However, about a fifth of patients with
seizures are still poorly controlled worldwide. It is important for the findings
from research to be translated into clinical practice.
Establish the correct diagnosis
Not all paroxysmal events are epileptic. Inappropriate treatment with anticonvulsants
is a frequent error. Ten to twenty percent of patients referred to neurology clinics
with epilepsy have alternative diagnoses. One should ask whether the patient has
experienced seizures before, as episodes of myoclonic jerks or partial seizures
may not be volunteered.
Conditions that mimic seizures should be considered. Syncope has characteristic
precipitating factors: premonitory features such as nausea, sweating and palpitations;
a transient unconsciousness of less than 25 seconds without disorientation or exhaustion
support this diagnosis. If the person cannot lie supine, for example when propped
up by bystanders, cerebral circulation is re-established more slowly and convulsive
syncope is more likely to occur.4
In epilepsy monitoring units, non-epileptic attack disorders (NEAD) such as "psychogenic
seizures" account for 30% of cases studied.5 Pelvic-thrusting, back arching,
side to side head movements, biting of the tip rather than the edge of the tongue
and tonic retrocollis are suggestive of NEAD.6 Although attacks may have
a strong emotional or psychological component, it is difficult to confirm this from
the history alone. Careful analysis of the patient's behaviour during a typical
attack and electroencephalogram (EEG) correlation can distinguish these from epileptic
seizures.7 Some patients may have combination of genuine convulsions
and psychogenic seizures. Parasomnias such as REM-sleep behaviour disorder or somnambulism
may be misinterpreted as nocturnal seizures.8
The physical examination may reveal subtle focal brain dysfunction which suggests
a diagnosis of partial or localisation-related epilepsy. These include facial asymmetry,
asymmetry of thumb size and pronation of outstretched hands. Skin abnormalities
are present in conditions with combined dermatological features and epilepsy, such
as tuberous sclerosis.9
Identify patients who require treatment
Antiepileptic drugs (AEDs) may be reasonably deferred after a first unprovoked seizure.
However the patient should be told that there is a chance of recurrence which is
about 40% in the subsequent two years.10
Patients with a first tonic-clonic seizure precipitated by factors such as exhaustion
or sleep deprivation do not need therapy. Lifestyle modifications may be sufficient
to prevent further attacks. Long term treatment should not be started in seizures
with a primary cause which is temporary such as hypoglycaemia or alcoholic withdrawal.11
When the benefits of treatment outweigh the problems of treatment-related side effects
or inconvenience, treatment should be initiated. AEDs may be prescribed after a
single unprovoked seizure if specific risk factors are present. These include presence
of structural brain lesion, a history of insult such as significant head trauma
or cerebral infection or status epilepticus at onset. In these conditions, the risk
of further seizures is much higher. There is no evidence that early treatment alters
the long-term prognosis for extended remission.12 In general, the use
of an AED as a diagnostic test is not recommended because of its placebo effect
and the availability of alternative tests to reach a positive diagnosis, such as
sleep EEG or video-telemetry.
Select the most appropriate drug
The choice of medication depends on the type of seizure.13,14 Carbamazepine,
phenytoin and lamotrigine have a strong action on the sodium channel and they are
employed for treating seizures which are focal in onset, based on clinical or EEG
findings.14-17 These include simple partial motor, complex partial and
tonic-clonic seizures. The side effect profile may also influence the choice of
drug. Carbamazepine may cause hyponatraemia and cardiac arrhythmias while phenytoin
is associated with cosmetic and cognitive side effects. (The seizure disorder of
some patients can be classified under a syndrome which may be responsive to a particular
AED. For example patients with juvenile myoclonic epilepsy respond well to valproate
but their symptoms are worsened with carbamazepine).18,19 Children or
adolescents, with generalised epilepsies may present with absences. They experience
a sudden onset of unresponsiveness and appear blank. The attack lasts for a few
seconds and terminates rapidly. Valproate and lamotrigine are used to treat this
type of seizure.19,20
Treatment should start with a single drug at a low dosage. This is particularly
important in elderly patients in whom seizures are usually partial in onset. For
example, carbamazepine should be started at 100 mg twice a day for one to two weeks
and then titrated to 200 mg twice a day.21
The dose should be increased as necessary to produce seizure control or until side
effects develop. The drug cannot be said to be ineffective until appropriate dosages
have been tried. It would be an error to substitute or add a new drug without an
adequate trial.19,22
Avoid unnecessary investigations
Therapeutic efficacy is judged by seizure control and the appearance of toxic effects.
Asymptomatic patients do not require regular blood tests if initial screening tests
were negative.23 Laboratory tests should be performed only when indicated.
(For example to help determine compliance in a patient with poor control or to review
drug levels in patients with altered pharmacokinetics). Routine blood tests are
ineffective in preventing serious toxicity.23,24
Drug levels should be interpreted with caution. Diagnosis of drug-induced side-effects
is based on clinical features. Some patients may have side effects even at low dose
of AED.
Avoid misinterpretion of EEG report
A normal EEG does not exclude epilepsy. The prevalence of a normal initial EEG in
persons with epilepsy is 50%. The likelihood of detecting inter-ictal epileptiform
discharges (IED) is influenced by age, the frequency and type of seizures (less
common in simple partial seizures) and the underlying neurological condition.25
A sleep study may demonstrate IEDs in 40% of epileptic patients with a normal recording
while awake. With serial recordings, the number of abnormal EEG increase to 60%.
In healthy individuals without a personal or family history of epilepsy, the probability
of an EEG showing epileptiform discharges such as spike or sharp waves is 0.5%.25
Artifacts, normal variants or normal physiological phenomena, such as vertex sharps
or ECG potentials may resemble epileptic discharges but are not pathological. When
epileptiform discharges are recorded, it is important to note whether the abnormal
activity is focal or generalised at onset. If the onset is focal, the epilepsy may
be due to an underlying structural pathology and would respond best to the drugs
mentioned above.
There is no association between EEG changes and clinical improvement. Routine follow-up
recordings at regular intervals are not useful. Any follow-up EEG should be performed
to address a specific clinical problem, such as to determine if a decline in cognitive
function is a result of subclinical seizures, drug toxicity or a progressive neurological
disease.
Avoid overtreatment
The lowest effective dose is generally recommended. In patients who continue to
have seizures on monotherapy, a second agent can be introduced. The initial drug
can be tapered off in most cases without an increase in seizure frequency.19,26
The maximum tolerated dose should be maintained only if there is significant reduction
in the intensity or frequency of seizures; otherwise the dose increments can be
reversed.
Treatment with unnecessarily high dosages may result in chronic drug toxicity.27
This is particularly important in women of child-bearing age. Pre-conceptual counselling
should be given and if possible converted to monotherapy, reduced to the lowest
effective dose and add folic acid, 2 to 5 mg per day to reduce the possibility of
teratogenicity.28
There is a lack of clinical evidence on whether AED working on different mechanisms
have an additive effect.
Identify psychosocial problems
Seizures are intermittent but the psycho-social burden is always present. Patients
may have misconceptions of their illness. Parents of the sufferers may be over-protective.
Pregnancy issues are a common concern. Although the commonly used AEDs may cause
malformations, over 90-95% of women with epilepsy have a normal pregnancy. Epilepsy
is not a contraindication to pregnancy. In general there should be few restrictions
on recreational activities. Television, computer and video games should be restricted
only when these are found to be a precipitating factor. Unsupervised swimming should
be avoided.
Refer patients with refractory epilepsy
Frequent generalised seizures, evidence of brain damage, low intelligence, failure
to achieve control readily are predictors of intractability. Ideally a magnetic
resonance scan (MRI) of the brain should be performed in all patients with uncontrolled
seizures.29 MRI may detect underlying lesions such as hippocampal atrophy
or cortical dysplasia which are beyond the resolution of CT scanning.30
Those with refractory epilepsy despite good compliance with one or two AEDs should
be referred for specialist assessment. Video-monitoring may clarify the diagnosis
and second-line AEDs can be introduced.31-33 Patients can also be evaluated
for non-pharmacological interventions such as vagal nerve stimulator implantation
or epilepsy surgery, consisting of anterior temporal lobectomy with amygdalo-hippocampectomy,
corpuscallosotmy and lesionectomy.34-39 In properly selected patients
the success rate in controlling seizure is approximately 70%.
Consider stopping antiepileptic drugs
In adults, the factors which are associated with successful drug withdrawal include
normal neurological examination and intelligence, normalisation of the EEG following
treatment, normal neuroimaging and the presence of only one type of seizure previously.40
The risk of relapse and the benefits of discontinuing AEDs (fewer side effects,
psychosocial benefits) should be discussed with the patient.41 Treatment
may be discontinued in patients with the above characteristics if they have been
free from seizures for two to three years. Seizure recurrence is about 25% in patients
without and over 50% in those with risk factors.
Key messages
- Magnetic resonance scan and Video-EEG are recommended investigational tools in patients
with refractory epilepsy.
- Push the first anti-epileptic drug tried and avoid polypharmacy as far as possible.
- Anticipate and address psychological and social consequences of epilepsy in addition
to seizure control.
- If patients are not responsive to one or two firstline drugs, consider referral
to neurologist in order to assess surgical amenability.
A C F Hui, MRCP, FHKAM
Senior Medical Officer,
Department of Medicine & Therapeutics, The Chinese University of Hong Kong.
H M Yeung, MRCP, FHKAM
Senior Medical Officer,
Department of Medicine, Alice Ho Miu Ling Nethersole Hospital.
Correspondence to : Dr A C F Hui, Department of Medicine & Therapeutics,
Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, N.T., Hong
Kong.
References
- McNamara JO. Emerging insights into the genesis of epilepsy. Nature 1999; 399(suppl):A15-A22.
- Henry TR. Progress in epilepsy research: functional neuroimaging with positron emission
tomography. Epilepsia 1996;37:1141-1154.
- Chadwick D. The use of new epileptic drugs. J R Coll Phy 1999;33:328- 332.
- Bleck TP. Syncope. In: Engels J, Pedley TA, (eds). Epilepsy: A Comprehensive Textbook.
Philadelphia: Lippincott-Ravren, 1998;2649-2659.
- Devinsky O, Sacuchez-Villasenor F, Vasquez B, et al. Clinical profile of patients
with epileptic and non-epileptic seizures. Neurology 1996;46:1530- 1533.
- Groeppel G, Kapitany T, Baumgartner C. Cluster analysis of clinical seizure semiology
of psychogenic non-epileptic seizures. Epilepsia 2000;41:610- 614.
- Porter RJ. Epileptic and non-epileptic events. In: Rowan AJ, Gates JR, (eds). Non-epileptic
seizures. Boston: Butterworth-Heinemann; 1993;9-21.
- Stores G. Confusions concerning sleep disorders and the epilepsies in children and
adolescents. Br J Psychiatr 1991;158:1-7.
- Aicardi J, Taylor DC. History and Physical Examination. In: Engels J, Pedley TA,
(eds). Epilepsy: A Comprehensive Textbook. Philadelphia: Lippincott-Raven; 1998;805-810.
- Berg AT, Shinnar S. The risks of seizure recurrence following a first unprovoked
seizure. Neurology 1991;41:965-972.
- Schmidt D. Overtreatment of epilepsy and how to avoid it. In: Schmidt D, Schachter
SC, (eds). Epilepsy: Problem Solving in Clinical Practice. London: Martin Dunitz,
2000;231-240.
- Musico M, Beghi E, Solari A, for the First Seizure Trial Group. Treatment of the
first tonic-clonic seizure does not improve the prognosis of epilepsy. Neurology
1997;49:991-998.
- Fong KY. Principles of management in epilepsy. JHKMA 1993;45:7-12.
- Leppik IE. Selecting treatment in patients with epilepsy. Hospital Practice. 2000;35:35-47.
- Mattson RH, Cramer JA, Collins JF, et al. A comparison of carbamazepine, phenobarbitol,
phenytoin and primidone in partial and secondarily generalised tonic-clonic seizures.
N Engl J Med 1985;313:145-151.
- Mattson RH, Cramer JA, Collins JF, et al. A comparison of valproate with carbamazepine
for the treatment of complex partial seizures and secondarily generalised tonic-clonic
seizures in adults. N Engl J Med 1992;327:765- 771.
- Brodie MJ, Richens A, Yuen AWC, for the UK Lamotrigine/Carbamazepine Monotherapy
Trial Group. Double blind comparison of Lamotrigine and Carbamazepine in newly diagnosed
epilepsy. Lancet 1995;345:476-479.
- Berkovic SF. Aggravation of generalised seizures. Epilepsia 1998;39 (suppl 3):S11-S14.
- Duncan JS. Principles of treatment of patients with chronic active epilepsy. In:
Shorvon S, Dreifuss F, Fish D, et al, (eds). The treatment of epilepsy. London;
Blackwell Science; 1996;177-190.
- Ferrie CD, Robinson RO, Knott C, et al. Lamotrigine as an add-on drug in typical
absence seizures. Acta Neurol Scand. 1995;91:200-202.
- Cloyd J. Commonly used antiepileptic drugs: age related pharmacokinetics. In: Rowan
AJ, Ramsay RE, (eds). Seizures and Epilepsy in the Elderly. Oxford: Butterworth-Heinemann,
1997;219-228.
- Schmidt D. The ten most relevant errors in the treatment of epilepsy. Epilepsia
1998;39(suppl 6):195.
- Pellock JM, Wilmore LJ. A rational guide to routine blood monitoring in patients
receiving antiepileptic drugs. Neurology 1991;41:961-964.
- Camfield P, Camfield C, Dooley J, et al. Routine Screening of blood and urine for
severe reactions to anticonvulsant drugs in asymptomatic patients is of doubtful
value. Can Med Assoc J 1989;14:1303-1305.
- Walczak TS, Prasanna J. Interictal EEG. In: Engels J, Pedley TA, (eds). Epilepsy:
A Comprehensive Textbook. Philadelphia: Lippincott-Raven; 1998; 831-848.
- Shorvon S, Reynolds EH. Unnecessary polypharmacy for epilepsy. Br Med J 1977;1:1635-1637.
- Greenwood RS. Adverse effects of antiepileptic drugs. Epilepsia 2000;41 (suppl 2):42-52.
- Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counselling, management,
and care of the pregnant women who with epilepsy. Neurology 1992;42(suppl 5):149-160.
- ILAE Neuroimaging Commission. ILAE Neuroimaging Commission recommendations for neuroimaging
of patients with epilepsy. Epilepsia 1997;38(suppl 10):1-2.
- Berkovic SF, Andermann F, Olivier A, et al. Hippocampal sclerosis in temporal lobe
epilepsy demonstrated by magnetic resonance imaging. Ann Neurol 1991;29:175-182.
- Sander JWAS. The new anti-epileptic drugs: their current role in the management
of epilepsy. Eur J Neurol 1996;3(suppl 3):15-20.
- Walker MC, Sander JWAS. The impact of new antiepileptic drugs on the prognosis of
epilepsy: total seizure control should be the ultimate goal. Neurology 1996;46:912-914.
- Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med 1996; 334:1583-1590.
- Uthman BM, Wilder BJ, Penny JK, et al. Treatment of epilepsy by stimulation of the
vagus nerve. Neurology 1993;43:1338-1345.
- First International Vagal Nerve Stimulation Study Group. A randomised controlled
trial of chronic vagal nerve stimulation for the treatment of medically intractable
seizures. Neurology 1995;45:224-230.
- Engel R. Update on surgical treatment of the epilepsies. Neurology 1993; 43:1612-1617.
- Sperling MR, O'Connor MJ, Saykin AJ, et al. Temporal lobectomy for refractory epilepsy.
JAMA 1996;276:470-475.
- Radhakrishnan K, So EL, Silbert PL, et al. Predictors of outcome of anterior temporal
lobectomy for intractable epilepsy: a multivariate study. Neurology 1998;51:465-471.
- Leung GKK, Fan YW, Fong KY. Temporal lobe resection for intractable epilepsy: review
of 1l cases. HK Med J 1999;5;329-336.
- American Academy of Neurology Quality Standards Subcommittee. Practice parameter:
a guideline for discontinuing antiepileptic drugs in seizure free patients-summary
statement. Neurology 1996;46:600-602.
- MRC Antiepileptic Drug Withdrawal Study Group. Randomised study of antiepileptic
drug withdrawal in patients in remission. Lancet 1991;337: 1175-1180.
|